Heart scanner - who's between a rock and a hard place? by Nel, T J
In conclusion, misoprostol has the potential to be an
extraordinarily useful drug in obstetric and gynaecological
practice, particularly in developing countries where
conventional prostaglandin preparations are unaffordable. As
its commercial registration for use in pregnancy appears
unlikely, clear gUidelines from the health authorities
regarding its use are urgently needed, coupled with
indemnity against complications which may be associated
with its use within these guidelines.
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Debate
Heart scanner - who's
between a rock and a hard
place?
I am a radiologist with a minor shareholding in the electron
beam computed tomography (EBCT) scanner discussed by
Ina van der Linde,' and feel compelled to comment on its
implied imminent demise.
Officialdom throughout the world demonstrates certain
traits. Words such as self-righteous, retention of control and
red tape spring to mind. They make endless rules which
when analysed translate into self-empowerment and
protection of their domain. South Africa in particular
personified this in its apartheid system. I believe that a
similar dynamic is at work with regard to the fate of EBCT.
The expensive EBCT scanner was imported after
assurance was received from the Radiology Society of
South Africa (RSSA) that conventional CT radiology codes
could be used for EBCT studies. At that time everyone,
including the RSSA, said that as EBCT was the only
machine capable of detecting and measuring coronary
artery calcification, a new code specific to this facet should
be applied for. This was done, and the EBCT machine was
ordered and subsequently installed in the Pretoria Heart
Hospital in mid-1997. Events orchestrated by 'officialdom'
resulted in the August 1997 Guide to Fees printing code
3598 for 'EBCT assessment of coronary artery calcification'
with no unit and no rand values. The days of old-fashioned
non-transparent kragdadigheid tactics are seriously
challenged when new official sleight-of-hand reaches such
heights. Not only are there no rand values, but hey presto,
the 311.80 units given to code 3598 by MASA in June 1997
have also disappeared! A barrage of warnings has also
emanated from the same officials, namely that code 3598
must be used for 'tracking purposes only' (and I thought the
pass laws were scrapped!) 'so that procedures using this
technology cannot be charged under existing codes.' Hence
Ina van der Linde's article heading, 'Heart scanner min
dae?', and her comment, 'does all this leave the HeartScan
SA team between a rock and a hard place?'
To throw more light on the subject I will provide some
background information. EBCT can perform conventional CT
examinations. However, its ability to perform CT scans
approximately 10 times faster than conventional scanners
gives EBCT unparalleled advantages where rapid image
acquisition is necessary, such as after trauma and in
paediatric patients. For example, a brain scan can be
performed in 2 seconds, avoiding the necessity of sedating
or anaesthetising a child for a diagnostic procedure. CT
angiography and organ perfusion analyses are examples
where the extremely rapid aquisition time of EBCT, together
with the use of less contrast medium, is distinctly
advantageous. Does RAMS realise this? They seem
determined to throw the EBCT baby out with the bathwater.
At present the abilities of EBCT are undoubtedly
maximised in cardiac analysis, where, prior to EBCT,
movement blurring bedevilled non-invasive cardiac imaging.
EBCTs short exposure time (with and without intravenous
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contrast) demonstrates cardiac anatomy with unrivalled
clarity and allows detailed functional analysis.
Histological examinations of postmortem hearts show that
coronary arterial calcification occurs exclusively in
atherosclerotic arteries and is absent in normal vessel walls.
The amount of coronary calcium is proportional to the
amount of atherosclerosis in the coronary arterial system.
A direct relationship has been established between·
coronary calcium, as measured by EBCT, and
atherosclerotic plaque detected with intravascular
ultrasound. About 20% of the total plaque burden is
represented as detectable coronary calcification by EBCT.
The presence and amount of calcium detected in a coronary
artery by EBCT indicates the presence, and correlates with
the amount, of associated atherosclerotic plaque (the so-
called 'tip of the atherosclerotic iceberg'). In one breath-hold
EBCT can detect coronary artery disease non-invasively and
painlessly. Surely this is a major advance?
Of the imaging modalities, only EBCT can detect and
quantify (calcium score) coronary artery calcification in the
living patient. EBCT calcium scores are calculated for each
main coronary artery, and the sum of these scores is the
total calcium score, which is proportional to the total plaque
burden in the coronary system. Follow-up on patients in
whom EBCT calcium scores had previously been performed
demonstrated that those with higher scores had significantly
more down-the-line coronary artery events than those with
low scores. Surely such risk stratification is valuable
information? We must learn to think of plaque burden, which
is associated with risk, and not only of lumenal stenosis,
which is associated with symptoms.
'Normal' calcium scores for age and gender in
westernised, industrialised populations have been
established. Comparing these with the patient's score
gauges the severity of the patient's disease. Given the fact
that cholesterol-lowering remedies work, the calcium score
taken in conjunction with the history, examination and risk
factor analysis of the patient guides the aggressiveness of
treatment, even in an asymptomatic patient. Makes sense to
me. Why does officialdom insist that there is no clinical
application?
Now let's examine some other issues. Of the 'necessity,
efficacy and affordability' that officialdom requests for the
introduction of new technology, the first two are to my mind
well proven for EBCT and the third must be considered in a
South African context. Should existing tests, such as stress
,ests in asymptomatic persons, not face up to the same
scrutiny?
Autopsies proved that significant coronary atherosclerosis
was present in young American soldiers killed in combat. In
untreated westernised patients this disease progresses over
decades. About 30% of fatal heart attacks occur suddenly in
asymptomatic people, hence coronary artery disease has
been named the 'silent killer'. It causes the most disease-
related fatalities in westernised societies. The costs of
cardiologists, cardiothoracic surgeons, hospitalisation,
coronary angiography, coronary stenting, bypass grafts in
theatre, medication and follow-up monitoring in the late
stages of the disease consume huge amounts of scarce
medical financial resources and have significant social and
industrial consequences. Early diagnosis of coronary
atherosclerosis using EBCT provides a large window of
opportunity, during which period inexpensive preventive
measures such as diet and lifestyle changes can be applied.
Exaggerated costs 'in excess of R100 million per annum' for
the utilisation of this modern technology are bandied about
with never a mention of the savings. Surely, as in every other
disease, early diagnosis should be encouraged? Why do we
have no preventive cardiology chair in this country?
Compensatory enlargement of the atherosclerotic artery
allows considerable intimal thickening (plaque formation)
before lumenal stenosis becomes apparent. It is well known
that sudden events take place in plaques which often lead
to compromise or occlusion of a coronary lumen - this is
when the patient recently passed by his doctor as having no
evidence of coronary heart disease succumbs to a fatal
heart attack. Cardiac symptoms, positive stress test results
and angiographically visible narrowings are all dependent on
significant lumenal stenosis. Considerable atherosclerosis
can be present in an asymptomatic patient in whom physical
examination, stress testing, cardiac ultrasound examination,
blood cholesterol and even angiography are 'normal'. Yet
these tests are commonly used to evaluate patients
suspected of having coronary artery disease. Is it not time to
add preViously unmeasurable happenings in the arterial wall
to the present obsession with the lumen? The appropriate
use of EBCT allows for early, accurate identification of
patien~s with coronary artery disease.
Two world leaders in preventive cardiology, Ors Stuart
Rich and Yadon Arad, both of whom have extensive
experience with EBCT, gave lectures in South Africa in mid-
1997. Why did Or Richard Tuft, head of the RSSA and the
Private Practice Negotiations Committee, and Or Aslam
Oasoo, head of RAMS, avoid making contact prior to, during
or subsequent to these lectures, despite invitations? Or Tuft,
wearing his RSSA hat, however, states that fBCT is a
'research tool' and 'must be controlled and monitored in an
academic environment'. How many black, previously poor
rural (Iow coronary artery risk), now middle-class urbanised
(high-risk) South Africans are likely to have heart attacks?
Perhaps EBCT could be used to identify them as something
uniquely South African. And where is this 'academic
environment' - in State hospitals? Is this realistic when
such hospitals haven't yet come to grips with installing less
expensive MRI machines?
Or Oasoo of RAMS, as advised by the RSSA,
recommends that medical aids should not pay for EBCT.
One reason is because it is a joint venture involving, inter
alia, cardiologists and radiologists (has this Immorality Act
not been scrapped?) with so-called 'perverse self-referral
incentives'. The trust that bought and owns the Pretoria
machine expects repayments to take place over 5 - 6 years
before there is any possible profit. If and when such profit
occurs, shareholder reimbursement will be proportional to
capital invested. This is perfectly legal and is a dilute
incentive when compared with present South African norms.
Cardiologists own their own ECG, stress ECG and
ultrasound equipment. Each time they use them they get
100% of the fee paid for the procedure by the medical aid
within about 60 days. Pulmonologists, surgeons and
gynaecologists who own and use lung function laboratories,
endoscopes and ultrasound machines are paid. Are these
not 'totally owned' ventures? Such common everyday
happenings, it seems, are not seen as 'self-referral', or as
SAMJ ~'o/!lme 8 So.5 .\1ay /998 __
having any 'perverse incentives.' Must a new test fulfil
different norms?
The RSSA advocates sole EBCT ownership by
radiologists. Would rearrangement of the present ownership
to that end result in its miraculous acceptance of the
modality? Why did Or Tuft, wearing his Private Practice
Negotiations Committee hat, recommend that 'the following
new item [code 3598] be introduced in the current Tariff
structure with immediate effect' in June 19971 Why, shortly
thereafter, did Or Tuft, wearing his RSSA hat, write to RAMS
saying 'If funds are allocated [to EBCT] we would request
they be not allocated to radiology'? Is this intended to stop
others from utilising the exclusive CT radiology toll road?
Amazingly, the RSSA allows vintage, unroadworthy, lethally
dangerous CT scanners 'with a matrix less than 250' to still
utilise this road, while the latest-model EBCT must drive on
its own pathway, which is landmined with code 3598! Is this
job reservation in the interest of the patient, who must now
pay for this test out of his pocket? What will happen to CT
colonoscopy, CT bronchoscopy and CT angiography? Who
will own MRI-guided operating theatres? Is the RSSA
positioning to have sole ownership of (and profit from) all of
these?
In summary, EBCT represents a quantum leap in
technology In terms of rapid image aquisition. This is of
special importance in the non-invasive early detection of
coronary heart disease. Ideally, patients at risk need a
thorough history and examination performed by any caring,
honest doctor, who will then refer some patients for
coronary artery calcium assessment by EBCT. The additional
value of the calcium score allows the knOWledgeable doctor
the best opportunity to appropriately advise and, if
necessary, cost-effectively administer tailored treatment to
the patie~t. Patients at risk, but having normal stress tests,
are less likely to accept medical advice and comply with
therapy than patients shown radiographs demonstrating the
distribution and extent of visible calcium deposits in their
own arteries. The calcium score and calcium distribution
alteration over time may prove to be a useful yardstick to
monitor coronary artery disease progression.
Continued dependence on inaccurate and misleading
tests, which medical aids pay for, wastes money, while
advising them not to pay for EBCT coronary calcium
assessment shows an irresponsible lack of concern for
patient well-being. Is the patient not between a rock and a
hard place if he or she must pay for this valuable test?
Some new aspects of imaging can no longer be restrained
by the artificial 'turf' compartments of conventional
medicine. The dirty linen of medical issues which may not
have the patient's best interests at heart will surely soon be
washed in well-publicised court cases, seriously damaging
the Image of conventional medicine. There is an urgent need
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Solid science and hard
logic - the rock on which
good treatment is based
With electron beam computed tomography (EBCT) it is now
possible to detect non-invasively and rapidly, and to a
degree to quantify, calcium deposition in coronary arteries.
This remarkable technique also allows for a detailed
evaluation of cardiac function and cardiac chamber volume
and mass, both at rest and during exercise. It is likely that
myocardial blood flow will soon be similarly quantifiable.' We
are therefore excited by the existence of this apparatus in
the Pretoria Heart Hospital. The ability to detect
intracoronary calcium, and implications deriving from the
fact that such deposition only occurs in diseased arteries,
has sparked major controversy in terms of the application of
this technique.
In this issue of the SAMJ Or Nel joins the controversy with
an impassioned appeal for widespread utilisation of EBCT
for existing or suspected coronary artery disease, either
clinically manifest or silent. The sociopolitical parallels he
draws, although poignant, are often somewhat obscure and
bitter, particularly in relation to issues of ownership and
payment. Much of the heat generated in this controversy
relates to appeals made directly to the general public, and is
often centred around the spectre of sudden cardiac death.
Thus the focus is both medical and fiscal.
An excellent, balanced and current overview of the
epidemiology, clinical implications, pathophysiology and
imaging of coronary artery calcification is offered in a
statement from the American Heart Association (AHA), to
which the reader is referred!
EBCT-detected coronary calcification can predict future
cardiac events, but not all of them.' It is a good predictor of
the need for revascularisation in both symptomatic and
asymptomatic3 patients, but a poor predictor of coronary
death or myocardial infarction.' This regrettably partly closes
the 'window of opportunity' optimistically referred to by Or
Nel. The reason for this inability to predict myocardial
infarction and infarction-related death is that although ECBT-
detected coronary calcium correlates well with the
established atherosclerotic plaque that can impair coronary
flow when large (the bigger the plaque the higher the
calcium score), thrombosis and infarction often occur in
unstable plaques lacking or low in calcium. They also occur
frequently in the absence of a heavily calcified overall plaque
load.'" Sudden cardiac death has causes other than acute
myocardial infarction. A major cause is predictable and
treatable ventricular arrhythmias. Here death is preventable
with implantable defibrillators, a fact proven in numerous
studies, but payment for the implantation has not been
guaranteed by the Representative Association for Medical
Schemes (RAMS).
There is an overall correlation between the total area of
detected coronary calcification and the total plaque load!"o
Unfortunately there is currently insufficent evidence that
EBCT can accurately track the total atherosclerotic load
over time. It therefore cannot act as a guide to whether
therapy is effective nor not. Although this may improve with
new technology, it has not been proved as yet.
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